Cargando…
Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries
INTRODUCTION: CAR T-cell therapy has emerged as a promising new immuno-oncology treatment that engages the patient’s immune system to fight certain hematological malignancies, including diffuse large B-cell lymphoma (DLBCL). In the European Union (EU), CAR T-cell therapies have been approved for rel...
Autores principales: | Canales Albendea, Miguel Á., Canonico, Pier Luigi, Cartron, Guillaume, Deiters, Barthold, Jommi, Claudio, Marks, Reinhard, Rioufol, Catherine, Sancho Cia, Juan M., Santoro, Armando, Wagner-Drouet, Eva M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263061/ https://www.ncbi.nlm.nih.gov/pubmed/37324138 http://dx.doi.org/10.3389/fmed.2023.1128295 |
Ejemplares similares
-
CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021) -
Comorbidities in DLBCL: too "Severe4" CAR-T therapy?
por: Qualls, David, et al.
Publicado: (2023) -
CAR T-Cell Therapies in Italy: Patient Access Barriers and Recommendations for Health System Solutions
por: Jommi, Claudio, et al.
Publicado: (2022) -
Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy
por: Lamure, Sylvain, et al.
Publicado: (2021) -
New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
por: Iqbal, Madiha, et al.
Publicado: (2021)